Ausgabe 2/2007
Inhalt (10 Artikel)
Unique Effect of Nebivolol on Coronary Hemodynamics: It’s All a Matter of Flow
Eli I. Lev, Alexander Battler
Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear
Jennifer G. Robinson, Helmut Schrott
Effect of β-Blockers on β3-Adrenoceptor Expression in Chronic Heart Failure
Qiang Zhao, Tong-Guo Wu, Zuo-Fen Jiang, Guo-Wei Chen, Yi Lin, Le-Xin Wang
The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress
Douwe J. Mulder, Paul L. van Haelst, Martgriet H. Wobbes, Rijk O. Gans, Felix Zijlstra, Johan F. May, Andries J. Smit, Jan Willem Cohen Tervaert, Jasper J. van Doormaal
Does the β-Blocker Nebivolol Increase Coronary Flow Reserve?
Mario Togni, Francesco Vigorito, Stephan Windecker, Linda Abrecht, Peter Wenaweser, Stephane Cook, Michael Billinger, Bernhard Meier, Otto M. Hess
Inverse Relationship between Lipid-lowering Drugs and Saturated Fat Intake in US Adults
Devin M. Mann, Sundar Natarajan
Long-term Risk of Ischemic Stroke Associated with Rofecoxib
Jonathan Afilalo, Michael J. Coussa-Charley, Mark J. Eisenberg
Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease
James P. Tsikouris, Michael J. Peeters
Advertising Campaigns of Sterol-Enriched Food. An Often Neglected Cause of Reduced Compliance to Lipid Lowering Drug Therapy
Alevizos Alevizos, Constantinos Mihas, Anargiros Mariolis